Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
Phase2Phase Biopharma Consulting AB
AB
Active
Org 5591207880
Nanna Svartz Väg 4, 171 65
Solna
Engineering activities and related technical consultancy
·
NACE 7112
Est. 2017 · 8 years old
5-9 employees
Monitor
Share
Sweden
/
Companies
/
Engineering activities and related technical consultancy
/
Phase2Phase Biopharma Consulting AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
21M
16M
11M
5M
0M
2021: 11M
11M
2021
2022: 17M (+55% vs 2021)
17M
+55%
2022
2023: 12M (-29% vs 2022)
12M
-29%
2023
2024: 11M (-8% vs 2023)
11M
-8%
2024
2025: 6M (-45% vs 2024)
6M
-45%
2025
EBITDA
SEK millions
6M
5M
3M
2M
0M
2021: 4M
4M
2021
2022: 5M (+25% vs 2021)
5M
+25%
2022
2023: 3M (-40% vs 2022)
3M
-40%
2023
2024: 3M (0% vs 2023)
3M
0%
2024
2025: 0M (-100% vs 2024)
0M
-100%
2025
Income statement
SEK thousands
Item
2025
2024
2023
2022
2021
Revenue
6 324
10 678
11 962
16 639
11 341
Staff expenses
−5 153
−7 335
−8 297
−8 571
—
EBITDA
372
2 509
2 552
4 980
4 331
Depreciation & amort.
—
—
—
—
−0
EBIT
372
2 509
2 552
4 980
4 331
Net financials
5
18
7
−927
−225
Profit before tax
2 316
1 687
1 134
1 433
3 141
Tax
−519
−395
−268
−470
−694
Net profit
1 797
1 292
866
963
2 447
Balance sheet
SEK thousands
Item
2025
2024
2023
2022
2021
Total assets
6 559
8 978
8 683
9 137
9 743
Equity
2 550
2 253
2 462
3 096
3 883
Long-term debt
—
—
—
—
0
Short-term debt
1 113
1 780
1 554
1 749
2 267
Total debt
1 113
1 780
1 554
1 749
2 267
Financial ratios
5-year trend
EBITDA margin
5,9 %
This company
15,8 %
Market median
This company
Market median
63% below market
2021
2025
Equity ratio
38,9 %
This company
38,2 %
Market median
This company
Market median
2% above market
2021
2025
Return on equity
70,5 %
This company
18,4 %
Market median
This company
Market median
283% above market
2021
2025
Net profit margin
28,4 %
This company
8,1 %
Market median
This company
Market median
251% above market
2021
2025
Asset turnover
0,96×
This company
1,12×
Market median
This company
Market median
14% below market
2021
2025
Debt / equity
1,57×
This company
0,62×
Market median
This company
Market median
153% above market
2021
2025
Annual reports & filings
Annual report 2025
Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
View
PDF
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
View
PDF
More on Phase2Phase Biopharma Consulting AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
